5 Things Every Mental Health Practice Should Know about the ICD-10 Transition

Check out our pipeline updates from October!

Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.

HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.

Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.

A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.

National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.

GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.

Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.